Squarepoint’s PharmaCyte Biotech PMCB Stock Holding History

Squarepoint’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,846	Closed	-$32.1K	–	4475
2023 Q4	$32.1K	Buy	+14,846	New	+$32.2K	﹤0.01%	3886

Other funds holding PMCB

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Squarepoint's PMCB Position: Q1 2024 in Review

Squarepoint sold out of PharmaCyte Biotech (PMCB) in Q1 2024, closing a stake of 14,846 shares — an estimated $32.1K sold.

Squarepoint first reported a position in PMCB in Q4 2023 and held it in 1 quarter. The position peaked at $32.1K in Q4 2023. 29 funds tracked by Wall St. Rank hold PMCB as of Q1 2024.

Squarepoint reported no remaining PharmaCyte Biotech position as of Q1 2024 after selling out during the quarter.
Squarepoint sold 14,846 PharmaCyte Biotech shares in Q1 2024, an estimated $32.1K.
Squarepoint first reported a position in PharmaCyte Biotech in Q4 2023 and held it in 1 quarter.
Squarepoint's PharmaCyte Biotech position peaked at $32.1K in Q4 2023.
29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.